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Abstract
Purpose: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that affects an
increasing number of patients. High comorbidity is observed between UC and other diseases in
which inflammation may be involved, including brain diseases such as cognitive impairment,
mental disorders, anxiety, and depression. To investigate the increased occurrence of these
brain diseases in patients with UC, non-invasive methods for monitoring peripheral and central
inflammation could be applied. Therefore, the goal of this study is to assess the feasibility of
monitoring gut and brain inflammation in a rat model of chemically induced colitis by positron
emission tomography (PET) with [11C]PBR28, a tracer targeting the translocator protein (TSPO),
which is upregulated when microglia and macrophages are activated.
Procedures: Colitis was induced in rats by intra-rectal injection of 2,4,6-trinitrobenzenesulfonic
acid (TNBS). Rats with colitis and healthy control animals were subjected to [11C]PBR28 PET of
the abdomen followed by ex vivo biodistribution in order to assess whether inflammation in the
gut could be detected. Another group of rats with colitis underwent repetitive [11C]PBR28 PET
imaging of the brain to investigate the development of neuroinflammation.
Results: Eleven days after TNBS injection, ex vivo biodistribution studies demonstrated
increased [11C]PBR28 uptake in the inflamed cecum and colon of rats with colitis as compared
to healthy controls, whereas PET imaging did not show any difference between groups at any
time. Similarly, repetitive PET imaging of the brain did not reveal any neuroinflammation induced
by the TNBS administration in the colon. In contrast, significantly increased [11C]PBR28 uptake
in cerebellum could be detected in ex vivo biodistribution studies on day 11.
Conclusion: Inflammation in both the gut and the brain of rats with chemically induced colitis was
observed by ex vivo biodistribution. However, these effects could not be detected by
[11C]PBR28 PET imaging in our colitis model, which is likely due to spill-over effects and
insufficient resolution of the PET camera.
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Introduction
Ulcerative colitis (UC) and Crohn’s disease are the major
types of inflammatory bowel disease (IBD). UC is a chronic
disease that is thought to be caused by a pathologicalCorrespondence to: E. Vries; e-mail: e.f.j.de.vries@umcg.nl
inflammatory response to intestinal microbes in genetically
susceptible patients [1]. UC is characterized by strong
inflammation in the colon and rectum that leads to diarrhea,
cramping, and pain [2]. The pathogenesis of IBD is still
poorly understood, and consequently, an effective treatment
is not available yet [3, 4]. High comorbidity between IBD
and brain diseases, including cognitive impairment [5],
mental disorders [6], anxiety, and depression [7–9], is
observed. Increasing evidence suggests that inflammation
plays a role in the development of these brain diseases [10–
13], and as a result, it is hypothesized that the comorbidity
between IBD and, e.g., depression is mediated by inflam-
mation via gut–brain interactions [14].
Evidence suggests that colitis can induce neuroinflam-
mation and affect brain functions. For example, in animals,
induction of colitis caused an increase in pro-inflammatory
cytokines, reduced neurogenesis in hippocampus [15] and
behavioral abnormalities such as cognition impairment, and
depression- and anxiety-like behavior which persisted after
the colonic inflammation had resolved [16, 17]. In humans,
the gut-brain interaction during colitis has been suggested to
be responsible for inflammation-mediated changes in gray
matter in patients with IBD [18]. Several lines of evidence
suggest that inflammation could be a promising target for the
treatment of colitis-related brain disorders such as depression
[19] or cognitive decline [20]. In fact, immunosuppressive
treatment was shown to ameliorate depressive symptoms in
patients with IBD [21].
In the clinic, the best way to diagnose colitis is by
colonoscopy. This method, however, is not suitable for
investigating the comorbidity of IBD. Non-invasive methods
can allow investigation of inflammation in peripheral tissues
and, more importantly, in the brain. Thus, adequate imaging
methods could help to increase our understanding of the
psychiatric comorbidities associated with colitis.
Positron emission tomography (PET) is a powerful tool
for non-invasive detection of inflammation both in animals
and in patients. So far, intestinal inflammation in humans
and mice was mainly assessed with PET imaging of glucose
metabolism with 2-deoxy-2-[18F]fluoro-D-glucose
([18F]FDG) [22–25]. This method, however, has some
limitations, as physiological [18F]FDG uptake can be found
in some patients [26]. Moreover, [18F]FDG uptake is not
specific for inflammation and it can be affected by various
factors, including stress and physical activity. Therefore,
more specific approaches with tracers targeting specific
inflammatory markers might be a good alternative for
[18F]FDG PET.
Colitis is characterized by massive infiltration of acti-
vated macrophages and other immune cells in the affected
colon. In the mitochondrial membrane of activated macro-
phages, the expression of 18-kDa translocator protein
(TSPO) receptors is strongly increased [27, 28]. In fact,
high levels of TSPO receptors were observed in the colon of
patients with IBD and in animal models of colitis [29, 40].
Therefore, the TSPO receptor could be a suitable biomarker
to monitor colitis-related intestinal inflammation. TSPO
receptors have already been used as an imaging biomarker
for neuroinflammation. [11C]PBR28 ([O-methyl-11C] N-
acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine)
was developed as a tracer for PET imaging of TSPO
expression in the brain. Based on biomathematical modeling
approaches, [11C]PBR28 PET demonstrated relatively low
test–retest variability in repeated measurements in the same
subject, high specific binding to TSPO receptors, and a good
signal-to-noise ratio as compared to the other TSPO tracers
[30]. We, therefore, selected [11C]PBR28 PET to investigate
whether gut and brain inflammation associated with colitis
could be detected in an animal model of chemically induced
colitis.
Several chemically induced animal models are used to
mimic UC in humans. Colitis induced with 2,4,6-
trinitrobenzenesulfonic acid (TNBS) is a widely used model
to monitor temporal changes in inflammatory markers and
other symptoms characteristic for UC. Intracolonic TNBS
administration causes chemically induced damage of the
intestinal mucosa, leading to the development of the
characteristic symptoms observed in UC patients, such as
diarrhea and presence of blood in the feces [31]. TNBS-
induced colitis in rats has also been used to study effects of
gut inflammation on the brain. TNBS administration in rats
was shown to induce activation of microglia and cytokine
release in the brain [32, 33] and increased expression of
intestinal TSPO receptors [40]. Therefore, we selected the
TNBS-induced colitis model for this study. The purpose of
the study was to investigate whether in vivo detection of the
activation of macrophages/microglia in the experimental
model of colitis with PBR28 PET is feasible.
Material and Methods
Experimental Animals
Animal experiments were performed in accordance with Dutch
Regulations for Animal Welfare. All procedures were approved by
the Institutional Animal Care and Use Committee of the University
of Groningen (protocol DEC6576D).
Male outbred Sprague Dawley rats (7 weeks of age, n = 24)
were purchased from Harlan (Horst, The Netherlands). Animals
were housed in thermo-regulated (21 ± 2 °C) and humidity-
controlled rooms under a 12–12 h light–dark cycle (lights on at
6:00 am) with ad libitum access to food (standard laboratory chow,
AIN93-G) and water. After arrival, the rats were housed in groups
and allowed to acclimatize for at least 7 days. Animals were single
housed during the experiment to allow individual measurement of
food intake and assessment of colitis symptoms.
Study Design
This study was divided into two parts. First, the abdominal imaging
followed by ex vivo biodistribution was performed. In the second
part, longitudinal brain imaging was performed. The time points for
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PET and ex vivo biodistribution were selected on day 4 and day 11
after TNBS administration based on literature data [32]. Day 4
represents the peak of inflammation in the gut, whereas inflamma-
tion was expected to be resolved by day 11.
In the first part of the study, rats were randomly divided into
three groups (n = 6 per group): (1) controls, (2) TNBS-injected
rats sacrificed on day 4 post-injection, and (3) TNBS-injected rats
sacrificed on day 11 post-injection (Fig. 1a). Rats received an
intra-rectal injection of TNBS under isoflurane anesthesia on day
0, and disease progression was monitored daily. Rats were
injected with [11C]PBR28, subjected to a 60-min PET scan of
the abdomen, and sacrificed approximately 65 min after the tracer
injection. This was followed by isolation of organs and tissues
(identified in Figs. 3f, 4, and 5a) for ex vivo biodistribution.
In the second part of the study, six healthy rats were subjected
to a baseline [11C]PBR28 PET scan of the brain (Fig. 1b). Two
weeks after the baseline PET scan, on experimental day 0, these
animals (n = 6) were intra-rectally injected with TNBS under
isoflurane anesthesia (see below). Further, rats were subjected to a
[11C]PBR28 PET scan of brain on day 4 and 11. Disease
progression was monitored during the whole period after TNBS
injection.
TNBS Injection
The rat model of TNBS-induced colitis was employed according to
a previously described method [32, 34]. Briefly, on experimental
day 0, rats were anesthetized with isoflurane (5 % induction and
3 % maintenance) mixed with oxygen. The abdomen was elevated
at approximately 45° and TNBS (30 mg/rat, in 1:1 [vol/vol]
mixture of absolute ethanol and saline) was injected into the colon
via a cannula which was carefully inserted into the rectum
(approximately 8 cm from the anus). The abdomen remained
elevated at approximately 45° for 30 min to avoid leakage of
TNBS. The body temperature of the rats was maintained with
heating pads; eye salve was applied onto the eyes to prevent
dehydration. Control animals were not subjected to any procedure
on experimental day 0 to avoid incidental inflammation due to
mechanical damage of the gut mucosa. After rectal TNBS
administration, rats were single housed, and body weight, food
intake, and feces condition were monitored daily. A 4-point scale
was applied to assess feces conditions: score 0 for normal feces, 1
for soft feces with a normal form, 2 for diarrhea, and 3 for the
absence of feces production.
PET Imaging
[11C]PBR28 with a radiochemical purity 999 % and a specific
activity of 210 ± 15 GBq/μmol were synthesized as previously
described [35]. The specific activity of [11C]PBR28 was not
significantly different between the experimental groups
(F(3) = 0.944, p = 0.439). PET scans were performed using a
dedicated small animal PET scanner (MicroPET Focus 220,
Siemens Medical Solutions, USA) in healthy animals or at day 4
or 11 after TNBS injection. Two rats from different experimental
groups were scanned simultaneously in each scanning session. The
body temperature of the rats was maintained with heating pads, eye
salve was applied onto the eyes to prevent dehydration, and heart
rate and blood oxygen levels were monitored with BioVet system
(M2 M Imaging, USA).
For abdominal PET imaging, rats were anesthetized with
isoflurane mixed with medical air (5 % induction and 3 %
maintenance) and a cannula was inserted into the tail vein for the
injection of the PET tracer. Rats were positioned in the PET camera
in a transaxial position with their abdomen in the center of the field
of view. A transmission scan of 10 min with a Co-57 point source
was performed and used to correct the PET data for attenuation,
scatter and random coincidences, and decay of radioactivity. After
completion of the transmission scan, [11C]PBR28 (29 ± 11 MBq)
was injected over a 1-min period and a 60-min emission scan was
started. There was no significant difference in injected [11C]PBR28
dose between the groups (F = 1.558, p = 0.254). Rats were
sacrificed after acquisition of the emission scan and tissues were
collected for ex vivo biodistribution.
To investigate whether microglia were activated as a results of
colitis induction, animals were subjected to PET imaging of the
brain at three time points. The scans were performed in the same
way as for the abdomen, except for the positioning of the animals
in the PET camera. Rats were positioned with their heads in the
center of the field of view. A bolus of 21 ± 9 MBq [11C]PBR28
was injected, with no statistically significant difference in injected
dose between time points (F = 0.173, p = 0.843). After the scan,
Fig. 1 Study design. a Three experimental groups were
injected with [11C]PBR28, subjected to PET imaging of the
abdomen and sacrificed for ex vivo biodistribution to
determine standardized uptake values (SUV) in various
organs and tissues. The healthy control group (n = 6, white)
was terminated at day 4. 2,4,6-Trinitrobenzenesulfonic acid
(TNBS) [30 mg/rat]-treated rats were terminated at either at
day 4 (n = 6, gray) or day 11 (n = 6, black). b A group of rats
(n = 6) was investigated by PET imaging of the brain 14 days
before TNBS injection (baseline) and 4 and 11 days after
TNBS injection.
70 Kurtys E. et al.: PET Imaging of Inflammation in Rat Colitis
rats were allowed to recover from anesthesia in their home cage,
which was placed on a heating pad for at least 2 h.
PET Image Reconstruction and Analysis
List-mode data of the [11C]PBR28 PET scans was separated into 21
frames (6 × 10, 4 × 30, 2 × 60, 1 × 120, 1 × 180, 4 × 300, and
3 × 600 s). Emission sinograms were iteratively reconstructed using
OSEM2D (4 iterations and 16 subsets). The [11C]PBR28 PET scans
of the abdomen were analyzed with Vinci 4.26 software (Max
Planck Institute for Neurological Research, Germany). Volumes of
interest (VOIs) of the abdomen were drawn manually. In the
exploratory analysis, VOIs of several sizes were drawn, giving
similar results. Final analysis was done with VOIs of 7015 mm3
(9,784 voxels). The [11C]PBR28 PET scans of the brain were
automatically co-registered with a tracer-specific template [36] and
spatially aligned with a stereotaxic T2-weigthed MRI template in
Paxinos space [37] using Vinci 4.26 software. For both abdominal
and brain imaging, a frame of 10 min, starting 50 min post-
injection, was chosen for analysis, as this time frame has been
shown to be the most stable in recent studies with [11C]PBR28 PET
[38]. Standardized uptake value (SUV) of the tracer for VOIs in the
abdomen and the brain were calculated as follows: [tissue activity
concentration (MBq/ml) × body weight (g)]/[injected dose (MBq)].
Ex Vivo Biodistribution
Control and experimental animals were sacrificed after abdominal
PET imaging, and the uptake of [11C]PBR28 in various tissues
identified was measured ex vivo. Samples from major organs,
bowels, and brain were collected and weighted. Radioactivity in the
tissues was measured with a gamma counter (LKB Wallace,
Finland). The results of biodistribution studies are expressed as
SUV according to the following equation: [tissue activity concen-
tration (MBq/ml) × body weight (g)]/[injected dose (MBq)], which
was calculated as indicated in the previous section. The same scale
(SUV) was used for both imaging and ex vivo biodistribution in
order to facilitate comparison between both measurements.
Statistical Analysis
Results are presented as mean ± standard deviation. Differences in
body weight, injected dose, and specific activity of [11C]PBR28
between the experimental groups were analyzed by one-way
ANOVA.
SUVs obtained from imaging and biodistribution studies were
analyzed by one-way ANOVA, followed by a Dunnett post hoc test
with the control groups as reference. A probability (p) value G0.05
was considered as statistically significant.
Results
Disease Symptoms
Rectal administration of TNBS resulted in the development
of clinical symptoms of colitis, which manifested as a
decrease in food intake and a decrease in body weight,
similar to what has been observed in previous studies [33,
34, 39]. On the experimental day 0, the body weight was
352 ± 24 g and did not differ significantly between the
groups (one-way ANOVA, F = 0.512, p = 0.61). As shown
in Fig. 2, food intake on day 1, post-TNBS injection, was
reduced by 90 ± 12 % (2.2 ± 2.6 g versus 21 ± 2 g,
F = 160.0, p G 0.0001). As a result, body weight was
reduced by 19 ± 4 g on day 2 after TNBS injection
(6 % ± 1 % as compared to day 0). By day 7, body weight
and food intake had recovered to baseline levels again.
Diarrhea was observed in all rats after TNBS treatment.
Some rats did not produce any feces for up to 2 days
following TNBS administration. In some animals, blood in
the feces and fecal adhesion to the anus was noted. The
consistency of the feces remained abnormal until sacrifice on
day 11 post-TNBS administration, indicating that the
animals had not fully recovered at the end of the experiment.
This was confirmed by the abnormal appearance of the
excised colon.
Fig. 2 Disease progression. Influence of colitis induced by intra-rectal injection of TNBS at day 0 on a food intake, b body
weight, and c feces score as a function of time. Fecal scored 0 = normal feces, 1 = soft feces, 2 = diarrhea, and 3 = no fecal
production. Data for food intake and body weight in healthy controls are represented by the values from day −6 to 0, before
TNBS injection. For the fecal score, no symptoms of colitis were observed in healthy animals (score 0). After day 7 following
TNBS injection, the feces score was 1 for all animals (therefore, no error bar is displayed). Data are presented as
mean ± standard deviation (n = 6). The animals did not undergo any other interventions or procedures within the displayed time
frame.
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Ex Vivo Biodistribution and PET Imaging of the
Abdomen
As shown in Fig. 3, abdominal [11C]PBR28 PET images of
control rats and rats treated with TNBS show a similar tracer
distribution. An unknown hotspot in the abdomen was
observed in all investigated groups (Fig. 3). By analyzing
different time frames of the PET scan, we observed that this
unknown hotspot was already clearly visible during the first
50 s of the scan (i.e., during the tracer injection), when the
tracer is supposed to be mainly present in the blood (Fig. 3a,
c). This implies that the observed hotspots are not
representing the (inflamed) colon, but probably represent
the blood vessels. The analysis of later frames showed that
hotspots located in blood vessels remain clearly visible until
the end of the 60 min scan and therefore the blood vessels
could be a potential pitfall when interpreting [11C]PBR28
PET images of the abdomen. On the images acquired
between 50 and 60 min after tracer injection, the highest
uptake is observed in the kidneys and in the blood vessels,
both in controls (Fig. 3b) and in TNBS-treated animals
(Fig. 3d). The inflamed colon could not be clearly
Fig. 3 PET imaging and ex vivo biodistribution of peripheral organs and tissues as a function of disease progression. Healthy
rats or TNBS-treated rats at either day 4 or day 11 post-TNBS injection were injected intravenously with [11C]PBR28
(29 ± 11 MBq) and subjected to the a 60-min PET scan of the abdomen under isoflurane anesthesia: examples of sagittal and
coronal sections showing the a first 50 s of the scan and b the last 10 min of the scan of a control rat; c the first 50 s of the scan
and d the last 10 min of the scan of a rat 4 days after TNBS injection; e abdominal uptake (SUV) of [11C]PBR28
[mean ± standard deviation] in TNBS-treated and control rats. Immediately after the PET scan (65 min after tracer injection),
animals were euthanized by cardiac puncture under deep sevoflurane anesthesia. Organs and tissues were harvested for
ex vivo biodistribution. [11C]PBR28 uptake in major organs and tissues as determined by f ex vivo biodistribution
(mean ± standard deviation). Statistically significant differences between TNBS-treated animals and the control group are
indicated with an asterisk: *p G 0.05 (ANOVA with Dunnett post hoc test).
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discriminated, and therefore, the whole abdomen was
analyzed. [11C]PBR28 uptake in the abdomen (excluding
kidney and visible blood vessels from the volume of interest)
did not reveal any differences between the groups (control:
SUV 0.62 ± 0.12, day 4 after TNBS injection: SUV
0.63 ± 0.03, day 11 after TNBS injection: 0.66 ± 0.04;
F = 0.288, p = 0.76).
Investigation of the intestinal tract by ex vivo
biodistribution on day 4 post-TNBS injection did not
reveal any significant differences between controls and
rats with colitis either. On day 11, however, signifi-
cantly higher [11C]PBR28 uptake was observed in
cecum and colon (2.23 ± 0.14 vs. 1.80 ± 0.28,
p = 0.02) of rats from the colitis group as compared
to controls (Fig. 4).
Ex vivo biodistribution studies of tissues beyond other
than the gastrointestinal tract at day 4 post-TNBS injection
demonstrated that radioactivity concentrations in plasma
(SUV 0.30 ± 0.08 vs. 0.20 ± 0.03, p G 0.01), whole blood
(SUV 0.39 ± 0.08 vs. 0.25 ± 0.04, p G 0.001), and liver
(SUV 1.31 ± 0.45 vs. 0.65 ± 0.14, p = 0.001) were
significantly higher in rats from the colitis group than in
controls. At day 11 post-TNBS injections, rats from the
colitis group had significantly higher tracer uptake in
kidneys than controls (SUV 8.30 ± 0.70 vs. 6.20 ± 2.20,
p = 0.024).
Ex Vivo Biodistribution and PET Imaging of the
Brain
As shown in Fig. 5a, ex vivo biodistribution showed no
significant differences in tracer uptake in the brain between
groups on day 4 post-TNBS injection. On day 11, however,
significantly higher tracer uptake in the cerebellum of
TNBS-treated animals than in controls was found (SUV
0.51 ± 0.09 vs. 0.43 ± 0.05, p = 0.043).
In contrast, PET imaging did not show any significant
differences in tracer uptake in cerebellum (F = 0.648,
p = 0.54) or whole brain (F = 1.069, p = 0.37) at any time
point after TNBS administration (Figs. 4b and 5c, d),
indicating that PET imaging was not sensitive enough to
detect the difference in TSPO expression observed in ex vivo
biodistribution studies.
Discussion
The goal of the present study was to investigate the
feasibility of detecting TNBS-induced inflammation in the
gut and the brain of rats using PET imaging with the TSPO-
targeting tracer [11C]PBR28. In humans, IBD is character-
ized by a strong peripheral inflammatory response. Previous
studies have shown that TNBS administration in the rat
colon causes symptoms similar to colitis in humans, such as
temporal diarrhea, rectal bleeding, decreased food intake,
and loss of body weight. These symptoms were also
observed in this study, indicating that colitis was indeed
present in the TNBS-treated rats.
Colitis involves inflammation of the gut and is accompa-
nied by infiltration of immune cells, including macrophages,
in the colon. We observed that TNBS injection caused an
increase in [11C]PBR28 uptake in cecum and the descending
colon. This would suggest that infiltrating macrophages with
elevated TSPO expression are present in these parts on the
intestinal tract. This observation is in agreement with studies
showing elevated TSPO expression in biopsies from patients
with chronic IBD and in tissue sections from the descending
colon of animals subjected to chemically induced colitis [29,
40].
Despite the elevated [11C]PBR28 uptake in the inflamed
intestines, no significant differences in intestinal uptake
between rats with colitis and controls could be detected by
PET imaging. PET images of the abdomen showed high
uptake of [11C]PBR28 in kidney and an unknown hotspot in
the abdomen, which was initially interpreted as being the
inflamed colon, due to the lack of any anatomical reference.
However, further investigation of the kinetics of the tracer
uptake demonstrated that the hotspot in the abdomen did not
represent the inflamed intestine, but the blood vessels. The
proximity of blood vessels to the colon may have prevented
detection of the inflamed colon by [11C]PBR28 PET. The
tracer uptake in the blood vessels is approximately threefold
higher than in the inflamed colon, and consequently, partial
volume and spill-over effects may have obscured the colon
on the PET images. Ex vivo biodistribution studies, on the
other hand, allow separation of the organs that are close
together in the body, and therefore, differences in
[11C]PBR28 uptake between groups could be detected by
this method. The differences in SUV values in cecum and
Fig. 4 Ex vivo Biodistribution of the intestines as a function
of disease progression. [11C]PRB28 uptake (60 min) in the
intestines of control rats (n = 6) and TNBS-treated rats
sacrificed at day 4 (n = 6) and day 11 (n = 6). Data are
presented as mean ± standard deviation. Statistically signif-
icant differences between TNBS-treated animals and the
control group are indicated with an asterisk: *p G 0.05
(ANOVA with Dunnett post hoc test).
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descending colon were significant but seem to be minor.
Studies on brain demonstrated high specificity of
[11C]PBR28 for TSPO receptors [40]. We hypothesize that
this minor effect could be due to relatively low levels of
TSPO receptor expression in rat colitis or due the fact that
basal [11C]PBR28 in the intestine is relatively high (it is
approximately five times higher than background uptake in
healthy brain, as measured with ex vivo biodistribution). For
that reason, it might be difficult to observe any effect of
inflammation.
It is important to notice that SUV values for the intestines
obtained from ex vivo biodistribution are approximately
threefold higher than those obtained by PET imaging. This
can be explained by the fact that in ex vivo biodistribution
feces, fluids, and gases inside the intestine are removed, and
therefore, do not contribute to the SUV. In PET imaging, on
the other hand, a region of interest is drawn around a section
of the gut, which includes not only the intestinal wall, but
also the contents of the intestine in the intraperitoneal space.
It seems likely that the concentration of activated macro-
phages is primarily located in the intestinal wall. Conse-
quently, the radioactivity signal that originates from the
activated macrophages in the colitis is diluted with the
radioactivity signal from feces, intestinal lumen, and
intraperitoneal space, resulting in a lower SUV for the total
region of interest. This cannot be avoided since the spatial
resolution of the PET camera is insufficient to draw a region
of interest around the intestinal wall alone.
In contrast to our results, other investigators using
[18F]DPA-714 as the PET tracer reported that the inflamed
colon could be visualized by PET in TNBS-injected animals.
They described significantly increased tracer uptake in the
colon of TNBS-injected rats 7 days after colitis induction, as
compared to healthy controls [41]. Remarkably, from the
DSS-induced model of colitis used in the same study for
ex vivo biodistribution, the reported absolute uptake of
[18F]DPA-714 in the colon as determined by PET was at
least an order of magnitude higher than the reported colon
Fig. 5 Ex vivo biodistribution and PET imaging of the brain. a Ex vivo biodistribution of [11C]PRB28 (65 min) in the brains of
control rats (n = 6) and TNBS-treated rats sacrificed at day 4 (n = 6) and day 11 (n = 6). b An example of a sagittal and coronal
[11C]PRB28 PET image of the brain of a rat subjected to TNBS treatment (day 4) and its overlay with a MRI template with
selected regions, as indicated by different colors and the numbers: 1 = cortex, 2 = caudate putamen, 3 = septum,
4 = hippocampus, 5 = cerebellum, 6 = thalamus, 7 = hypothalamus, 8 = pons + medulla. [11C]PRB28 uptake (50–60 min) in c
whole brain and d cerebellum was measured by PET imaging. Data are presented as mean ± standard deviation. Statistically
significant differences between TNBS-treated animals and the control group are indicated with an asterisk: *p G 0.05 (ANOVA
with Dunett post hoc test).
74 Kurtys E. et al.: PET Imaging of Inflammation in Rat Colitis
uptake of [18F]DPA-714 as measured by ex vivo
biodistribution. This suggests that [18F]DPA-714 PET data
in the colon may have been affected by a substantial spill-
over effect as well, possibly from the blood vessels or the
intestinal contents. In the future studies, PET should ideally
be combined with simultaneous measurement of contrast-
enhanced CT or MRI in order to correctly localize the colon
and thus to allow better detection of differences in tracer
uptake between conditions. Moreover, localization of the
inflamed colon and reducing spill-over from the blood
vessels could also be facilitated by injecting TNBS in the
proximal colon, rather than in the distal colon, as demon-
strated in previous studies [41].
When comparing the ex vivo biodistribution results of
our study with the reported data for [18F]DPA-714 in DSS-
colitis model [41], [11C]PBR28 uptake in the colon of
TNBS-treated rats was approximately tenfold higher than
[18F]DPA-714 uptake. However, the reported relative
difference between the colitis group and controls is much
larger for [18F]DPA-714 than the difference that we
observed for [11C]PBR28. This suggests that the relatively
high background uptake of [11C]PBR28 in the healthy gut
may have led to insufficient contrast to detect colitis in
rats. However, comparison between the studies should be
interpreted with care, since not only different PET tracers
were used, but also different time points after TNBS
injection were investigated. Therefore, disease severity
(i.e., inflammation) may have been different between the
two studies.
TNBS administration did not only affect [11C]PBR28
uptake in the intestines, but also in liver, plasma, whole
blood (day 4), and kidneys (day 11). This is consistent with
the previous studies demonstrating the distribution of
[11C]PBR across the organs and its metabolic fate (renal
clearance) [42]. The increase in [11C]PBR28 retention in the
blood probably reflects the binding of the tracer to immune
cells that were activated as a result of the experimental
colitis. Since the blood content in the liver is high
(approximately 30 %), elevated blood radioactivity levels
could also explain the increased tracer uptake in the liver.
Moreover, the increased tracer uptake in the liver could also
be due to distinct changes in the dendritic cell and
macrophage composition in the liver as a result of acute
and chronic intestinal inflammation [43]. Previous studies
have also shown crosstalk between the gut and kidney
during colitis [44, 45]. Chemically induced colitis generates
inflammatory mediators that are responsible for neutrophil
infiltration in the kidney, resulting in acute kidney injury.
Anti-inflammatory agents or knock-out of chemokine recep-
tors could suppress the colitis-induced kidney injury [44,
45]. Thus, infiltration of activated macrophages may have
been responsible for the elevated tracer uptake in the
kidneys.
Likewise, the experimental colitis seems to have caused
activation of microglia or infiltration of macrophages in the
brain, as ex vivo biodistribution studies revealed a small,
but significant increase in [11C]PBR28 uptake in cerebel-
lum 11 days after TNBS administration. In the previous
studies, microglia activation in cerebellum has not been
investigated, but it has been demonstrated in hippocampus
at day 4 following TNBS treatment [32]. This effect,
however, was not detected in our study; this could be
caused by the difference in sensitivity of the PET tracer as
compared to immunohistochemistry. In contrast to ex vivo
biodistribution, repetitive [11C]PBR28 PET imaging could
not reveal any activation of microglia or infiltration of
peripheral macrophages in the brain as no significant
differences in cerebral or cerebellar tracer uptake were
observed between rats with colitis and controls.
Conclusions
To summarize, interaction between intestinal inflammation
associated with IBD pathology with the brain immune
system may explain several brain-related comorbidities
observed in patients with IBD. Longitudinal monitoring of
inflammation in both the gut and the brain in animal models
and in patients with colitis is necessary to confirm this
hypothesis. For this purpose, it is essential to validate
methods for reliable non-invasive measurement of inflam-
mation that can be used both in animal studies and in clinical
trials. In this study, we investigated the feasibility of
monitoring brain and gut inflammation in a rat model of
TNBS-induced colitis with [11C]PBR28 PET and organ
harvesting. Intestinal inflammation, kidney infiltration, and
mild neuroinflammation were detected in ex vivo
biodistribution studies. However, these effects could not be
detected by imaging in our colitis model due to an
insufficient sensitivity of the technique. This may be caused
by spill-over effects as a result of the limited resolution of
the PET camera or by insufficient contrast to detect subtle
changes in microglia/macrophage activation due to the fact
that the background signal of [11C]PBR28 is still too high
(although, it is lower than for many other TSPO tracers). On
the other hand, the lack of detection of TSPO receptors with
PET imaging could be caused by insufficient expression
of these receptors. Although previous studies have
demonstrated TSPO expression following TNBS injection
[40], it is possible that more severe model with higher
TNBS dose should have been applied here. This,
however, still supports the hypothesis that PET imaging
with [11C] is not a sensitive method for the detection of
gut and brain inflammation in TNBS-induced colitis in
rats.
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